We are live on ! Find out more
MREO

Mereo BioPharma
MREO

60 hedge funds and large institutions have $99.6M invested in Mereo BioPharma in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

8,000% more call options, than puts

Call options by funds: $81K | Put options by funds: $1K

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

1.52% more ownership

Funds ownership: 13.67% → 15.19% (+1.5%)

17% less funds holding

Funds holding: 72 → 60 (-12)

32% less capital invested

Capital invested by funds: $146M → $99.6M (-$46.1M)

80% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 15

Holders
60
Holders Change
-12
Holders Change %
-16.67%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
22
Reduced
12
Closed
15
Calls
$81K
Puts
$1K
Net Calls
+$80K
Net Calls Change
+$118K

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$13.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.14M
3
CC
Clearline Capital
New York
+$796K
4
RSCM
Rock Springs Capital Management
Maryland
+$633K
5
BlackRock
BlackRock
New York
+$360K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$4.02M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.6M
3
SCP
Sender Company & Partners
New York
-$534K
4
CAM
Connacht Asset Management
New York
-$341K
5
Marshall Wace
Marshall Wace
United Kingdom
-$157K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$19.3M +$13.1M +10,154,810 New
RCMNY
2
Rubric Capital Management (New York)
New York
$16.8M +$111K +85,553 +0.6%
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$12.9M +$1.14M +885,000 +8%
SCM
4
Suvretta Capital Management
New York
$10.2M – – –
RSCM
5
Rock Springs Capital Management
Maryland
$6.8M +$633K +489,322 +9%
Citadel Advisors
6
Citadel Advisors
Florida
$4.38M -$122K -94,479 -2%
VC
7
Vivo Capital
California
$4.25M -$4.02M -3,111,964 -45%
HA
8
HHLR Advisors
Cayman Islands
$3.33M – – –
Holocene Advisors
9
Holocene Advisors
New York
$2.84M +$89.3K +69,090 +3%
CC
10
Commodore Capital
New York
$2.19M – – –
Alkeon Capital Management
11
Alkeon Capital Management
New York
$2.17M – – –
TCM
12
Tekla Capital Management
Massachusetts
$1.74M – – –
AG
13
Artal Group
Luxembourg
$1.68M – – –
CC
14
Clearline Capital
New York
$1.46M +$796K +615,491 +90%
DCM
15
DAFNA Capital Management
California
$1.36M +$116K +90,000 +8%
Millennium Management
16
Millennium Management
New York
$1.03M -$42.6K -32,976 -3%
SSA
17
Schonfeld Strategic Advisors
New York
$984K +$205K +158,330 +22%
BlackRock
18
BlackRock
New York
$840K +$360K +278,729 +59%
Goldman Sachs
19
Goldman Sachs
New York
$801K +$3.65K +2,822 +0.4%
MS
20
Maven Securities
Jersey
$610K +$296K +229,001 +73%
Barclays
21
Barclays
United Kingdom
$477K +$68.9K +53,291 +14%
State Street
22
State Street
Massachusetts
$458K – – –
EP
23
Eversept Partners
New York
$415K +$143K +110,700 +43%
Primecap Management
24
Primecap Management
California
$371K -$1.68K -1,300 -0.4%
IC
25
Ikarian Capital
Texas
$318K +$80.4K +62,176 +7%
1
2 3

MREO Hedge Fund Activity: Q1 2022 in Review

60 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q1 2022, worth a combined $99.6M — down 32% from $146M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of MREO and 3 opened new positions — a net loss of 12 holders — while 12 trimmed existing stakes and 22 added.

The largest buyer was OrbiMed, opening a new position worth an estimated $13.1M. The largest seller was Vivo Capital, cutting an estimated $4.02M.

  • 60 institutional investors held Mereo BioPharma (MREO) as of Q1 2022, down from 72 in Q4 2021.
  • Funds reported $99.6M of Mereo BioPharma stock for Q1 2022, down 32% quarter-over-quarter.
  • 3 funds opened new Mereo BioPharma positions in Q1 2022 and 15 closed out, a net change of -12 holders.
  • The largest Mereo BioPharma buyer in Q1 2022 was OrbiMed, an estimated $13.1M added.
  • The largest Mereo BioPharma seller in Q1 2022 was Vivo Capital, an estimated $4.02M sold.

Based on aggregated 13F filings for Q1 2022.